XR 5942
Alternative Names: XR-5942Latest Information Update: 29 Jul 2004
At a glance
- Originator Xenova Group
- Class
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Jul 2004 Discontinued - Preclinical for Cancer in United Kingdom (PO)
- 28 Jul 2000 New profile
- 28 Jul 2000 Preclinical development for Cancer in United Kingdom (PO)